Integra LifeSciences delivered fourth-quarter 2025 revenues of $434.9 million, a 1.7% decline on a reported basis and a 2.5% drop organically compared to the prior year. The company recorded a GAAP net loss of $1.7 million or $0.02 per diluted share, while adjusted net income was $63.7 million or $0.83 per share, and adjusted EBITDA reached $104.2 million (24.0% margin).

Codman Specialty Surgical, representing 75% of revenues, generated $323.3 million in Q4, up 2.7% reported and 1.6% organically, driven by double-digit growth in CereLink® and strong Neurosurgery instrument sales. Tissue Technologies, at 25% of revenues, posted $111.6 million, down 12.8% both reported and organic, with a 21.4% decline in Wound Reconstruction offset partly by 20.1% growth in private label.

Full-year revenues were $1,635.2 million, a 1.5% increase on a reported basis and a 0.7% organic decline. The company incurred a GAAP net loss of $516.5 million, or $6.74 per share, driven by a $511 million goodwill impairment, while adjusted EBITDA was $317.5 million (19.4% margin) and adjusted net income came in at $171.4 million or $2.23 per share.

A simplified operating model was implemented to enhance alignment, accountability and drive long-term margin improvement, underpinning anticipated cost savings of $25–30 million in 2026. Operational milestones include strengthened quality management, compliance advancements and the early relaunch of PriMatrix® and Durepair™ products.